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determine whether hypoxia per se was an independent and clinically 
relevant risk factor for thrombosis. We believe that this issue de-
serves further investigation and that future studies on thrombosis 
in COVID-19 patients should be designed to assess the independent 
contribution of hypoxia to the development of thrombosis.
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Response to Maccio et al, “Multifactorial pathogenesis of 
COVID-19-related coagulopathy: Can defibrotide have a role in 
the early phases of coagulation disorders?”
We read with interest the letter by Maccio et al, which postulates a 
role for defibrotide (DF) in the treatment of coagulation disorders 
observed in COVID-19.1 Their commentary effectively explores the 
contribution of macrophages toward the coagulopathy observed in 
COVID-19, while highlighting the similarities between COVID-19–
associated vascular lesions and veno-occlusive disease (VOD), also 
known as sinusoidal obstruction syndrome (SOS) and commonly re-
ferred to as VOD/SOS. DF has indeed been shown to improve over-
all survival in patients with severe VOD/SOS2 and may be beneficial 
in the treatment of COVID-19, but not exclusively because of the 
observed similarities to VOD/SOS.
In detailing the role of macrophages in COVID-19–related co-
agulopathy, the letter overlooks some other etiologies. While 
macrophages may drive endothelial dysfunction by production of 
reactive oxygen species (ROS) and pro-inflammatory cytokines, the 
endotheliopathy observed in COVID-19 may also be driven by direct 
infection of endothelial cells by SARS-CoV-2.3
Angiotensin converting enzyme 2 (ACE2) receptors mediate the 
entry of SARS-CoV-2 into the cell, via direct interaction between 
ACE2 and primed viral spike proteins. ACE2 is expressed abundantly 
on lung alveolar epithelial cells and enterocytes of the small intestine 
but is also present in arterial and venous endothelial cells, pericytes, 
and vascular smooth muscle cells across numerous organ systems.4 
Direct infection and apoptotic death of endothelial cells by SARS-
CoV-2 has been demonstrated across vascular beds of several or-
gans via post mortem histology.3
The p38 mitogen-activated protein kinase (MAPK) pathway may 
be a critical factor in COVID-19–related endotheliopathy. Similar to 
other respiratory RNA viruses, SARS-CoV-2 infection induces upreg-
ulation of p38 MAPK, perhaps enhancing viral replication.5 More no-
tably, however, the entry mechanism of SARS-CoV-2 disables a key 
homeostatic process employed by the cell to diminish p38 MAPK 
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downstream of angiotensin II (Ang II) signaling. ACE2 on the cell sur-
face converts Ang II into angiotensin 1-7, which binds the Mas recep-
tor and downregulates the vasoconstrictive and proinflammatory 
effects driven by Ang II through p38 MAPK activation. Binding of 
ACE2 by SARS-CoV-2 leads to endocytosis and proteolytic cleavage, 
resulting in decreased ACE2 expression and functionality, thereby 
diminishing the counterbalancing effect served by ACE2.4 The result 
is upregulation of p38 MAPK, which activates the transcription of 
proinflammatory cytokines such as interleukin (IL)-6, tissue necrosis 
factor (TNF)-alpha, and IL-1beta, all of which are detected at high 
levels in patients with COVID-19. Unchecked p38 MAPK activity 
may thereby promote endotheliitis, vasoconstriction, and thrombo-
sis while also augmenting the viral life cycle.6
DF has been demonstrated to decrease p38 MAPK activation 
through direct interaction with endothelial cells,7 and DF treatment 
of COVID-19 may serve to target this signaling axis in COVID-19–re-
lated endotheliopathy. Studies have demonstrated increased integrin 
ligand expression, disrupted endothelial cell membranes, and peri-
vascular inflammation in COVID-19, all of which may also contribute 
to endothelial cell dysfunction and disseminated intravascular coag-
ulation observed clinically.7,8 In murine models, DF downregulates 
the expression of endothelial cell adhesion molecules that are criti-
cal to platelet activation and leukocyte migration such as P-selectin, 
E-selectin, vascular cell adhesion molecule (VCAM), and intercellular 
adhesion molecule (ICAM)-1, and lowers endothelial cell release of 
pro-inflammatory cytokines.9 In addition, the severity of COVID-19 
has been linked to heparanase activity, with significant elevations of 
heparanase reported in COVID-19 patients.10 As a key regulator of 
inflammation at the endothelium, heparanase likely plays a central 
role in COVID-19–related vasculitis and thrombosis. DF potently in-
hibits both heparanase expression and enzymatic activity, furthering 
its significant potential as a treatment for COVID-19.2,7,9
In the ongoing Spanish DEFACOVID phase IIb randomized clini-
cal trial (clinicaltrials.gov: NCT04348383), as well as other interna-
tional studies either planned or already under way in Italy, the United 
States, Ireland, and the United Kingdom, patients treated with DF 
are being comprehensively assessed for serum plasma inflammatory 
markers, including heparanase, pro-inflammatory and anti-inflam-
matory cytokines, immune subpopulation cells, and prothrombotic/
antifibrinolytic markers such as von Willebrand factor and soluble 
thrombomodulin. Preliminary results are encouraging to date, and 
these data will hopefully serve to demonstrate the effects of DF on 
the proposed targets in COVID-19.
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Defibrotide in the COVID-19 coagulopathy: What is the timing?
Dear Editor,
We appreciate the insightful comments by Richardson et al1 about 
our letter,2 which contributed to better explore the fundamental 
concepts of our study by providing important, additional informa-
tion for reflection.
The identification of additional mechanisms involved in the en-
dothelial damage as that described by Richardson et al1 mediated by 
the p38 MAPK pathway, which is upregulated as a result of the bind-
ing of SARSCoV2 on ACE2 receptors on the surface of endothelial 
cells and, in turn, activates the transcription of the proinflammatory 
cytokines, poses an important problem regarding the timing of the 
onset of coagulopathy in patients with COVID-19. Consequently it 
is fundamental to understand the timing of the start of anticoagu-
lant therapy based on the drugs available to date3 to establish a tar-
geted etiopathogenesis approach (ie, based on the etiopathogenesis 
mechanisms).
The subdivision of COVID-19 into different stages (paucisymp-
tomatic, mild, and critically severe) would reinforce this exigency, 
and strongly requires us to understand when the coagulopathy be-
gins. Therefore, it is essential to pay attention to the specific phases 
of the defense mechanism of our body against the pathogen in order 
to improve our understanding of what happens during the course 
of COVID-19. SARSCoV2 infection, as previously described, involves 
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